Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05179577 (ClinicalTrials.gov)	June 2023	12/11/2021	A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis (Study OS440-3006)	Spasticity	Drug: Arbaclofen;Drug: Placebo	RVL Pharmaceuticals, Inc.	NULL	Not yet recruiting	18 Years	65 Years	All	442	Phase 3	NULL
2	NCT02869425 (ClinicalTrials.gov)	July 2016	3/8/2016	To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS	A Randomized, Double-Blind, Parallel-Group Study to Assess the Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With Multiple Sclerosis	Multiple Sclerosis;Sperm	Drug: arbaclofen ER Tablets;Drug: Placebo for arbaclofen ER tablets	RVL Pharmaceuticals, Inc.	Osmotica Pharmaceutical US LLC	Withdrawn	18 Years	55 Years	Male	0	Phase 3	United States
3	NCT01743651 (ClinicalTrials.gov)	November 2012	28/11/2012	Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis	A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis	Spasticity;Multiple Sclerosis	Drug: arbaclofen;Drug: baclofen;Drug: Placebo	RVL Pharmaceuticals, Inc.	Osmotica Pharmaceutical US LLC	Completed	18 Years	65 Years	All	353	Phase 3	United States;Russian Federation;Ukraine